BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) has announced key leadership changes in its research and development and business development teams. Effective September 30, Greg Friberg, M.D., will join the company as Executive Vice President and Chief Research & Development Officer, succeeding…
WuXi Biologics (Cayman) Inc. (“WuXi Biologics” or “the Group”, stock code: 2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) providing comprehensive solutions for biologics discovery, development, and manufacturing, has announced its unaudited interim results for the first…
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company specializing in novel small molecule therapeutics from its boron chemistry platform, has announced the adoption of a limited-duration stockholder rights plan. This plan is set to expire on August 15, 2025. The…
Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company dedicated to developing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases influenced by protein growth factors, today announced the granting of inducement equity awards to five newly hired…
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been conditionally approved in China for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have undergone two or more prior treatments. The approval by the…
Bio-Techne’s fourth quarter organic revenue increased by 1% (2% reported) to $306.1 million. For the full year, organic revenue rose by 1% (2% reported) to $1.2 billion. GAAP earnings per share (EPS) for the fourth quarter were $0.25, down from…
Today, the European Commission (EC) approved ADZYNMA®▼ (recombinant ADAMTS13) for treating ADAMTS13 deficiency in both children and adults with congenital thrombotic thrombocytopenic purpura (cTTP). ADZYNMA is now the first and only enzyme replacement therapy in the European Union (EU) specifically…
Eli Lilly today announced its Q2 2024 financial results, highlighting strong performance driven by Mounjaro, Zepbound, and Verzenio, along with significant advancements in global manufacturing. David A. Ricks, Lilly’s chair and CEO, emphasized the company’s growth in treating cancer, neurological…
Operating profit rose by 18% in Danish kroner and 19% at constant exchange rates (CER) to DKK 57.8 billion, despite a DKK 5.7 billion impairment loss related to ocedurenone. North America Operations saw a 36% sales increase in Danish kroner…
Rite Aid Announces Flu and RSV Vaccine Appointments Available at All Locations Rite Aid has announced that appointments for both influenza (flu) and respiratory syncytial virus (RSV) vaccines are now available at all store locations, including Bartell Drugs in the…
Imbrium Therapeutics L.P. (“Imbrium”), a subsidiary of Purdue Pharma L.P. (“Purdue”), has submitted an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) to evaluate sunobinop for the potential treatment of moderate to severe alcohol use…
Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company focused on developing innovative biologic therapeutics, announced today that it has received approval from the European Medicines Agency (EMA) to commence a Phase 1 clinical trial of JK06 in various solid tumors…